THYROLAR 1 Rx
Generic Name and Formulations:
Liotrix (contains liothyronine sodium (T3) 12.5mcg and levothyroxine sodium (T4) 50mcg); tabs.
Indications for THYROLAR 1:
Hypothyroidism: initially one tab of Thyrolar 1/2 daily (long-standing myxedema: initially one tab of Thyrolar 1/4 daily); increase by one tab of Thyrolar 1/4 every 2–3 weeks; usual maintenance: one tab of Thyrolar 1 to one tab of Thyrolar 2 daily. Myxedema coma: see literature.
Hypothyroidism: <6months: one tab of Thyrolar 1/4 to one tab of Thyrolar 1/2 daily. 6–12months: one tab of Thyrolar 1/2 to one tab of Thyrolar 1/2 + one tab of Thyrolar 1/4 daily; 1–5yrs: one tab of Thyrolar 1/2 + one tab of Thyrolar 1/4 to one tab of Thyrolar 1 daily; 6–12yrs: one tab of Thyrolar 1 to one tab of Thyrolar 1 + one tab of Thyrolar 1/2 daily; >12yrs: more than one tab of Thyrolar 1 + one tab of Thyrolar 1/2 daily.
Uncorrected adrenocortical insufficiency. Untreated thyrotoxicosis.
Not for treatment of obesity. Cardiovascular disease, angina, elderly: use lower initial dose. Adrenocortical insufficiency. Monitor for craniosynostosis in infants. Pregnancy (Cat. A). Nursing mothers.
T3 and T4 (synthetic).
Monitor oral anticoagulants, hypoglycemics. Estrogens affect thyroid function tests. Toxicity with larger doses of sympathomimetics (e.g., anorectics).
Hyperthyroidism; transient hair loss in children.
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Smartphone App Helps Evaluate Catastrophizing in Chronic Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Dozens of Medical Groups Join Forces to Improve Diagnoses
- FDA Grants Non-Opioid Analgesic VVZ-149 Fast Track Status
- Little to No Association Found Between Physician Performance and Medical School Ranking